Sarepta Therapeutics, Inc. SRPT Business Segments — Roche Collaboration Reimbursement
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept srpt:RocheCollaborationReimbursement.
The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sarepta Therapeutics, Inc.'s business segments — roche collaboration reimbursement.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sarepta Therapeutics, Inc.'s business segments — roche collaboration reimbursement?
- Sarepta Therapeutics, Inc. (SRPT) reported business segments — roche collaboration reimbursement of -$8.19M in Q1 2026.
- How has Sarepta Therapeutics, Inc.'s business segments — roche collaboration reimbursement changed year-over-year?
- Sarepta Therapeutics, Inc.'s business segments — roche collaboration reimbursement increased by 71.2% year-over-year, from -$28.48M to -$8.19M.
- What is the long-term trend for Sarepta Therapeutics, Inc.'s business segments — roche collaboration reimbursement?
- Over 3 years (2022 to 2025), Sarepta Therapeutics, Inc.'s business segments — roche collaboration reimbursement has grown at a -10.4% compound annual growth rate (CAGR), from -$117.81M to -$84.73M.
- What does business segments — roche collaboration reimbursement mean?
- Tracks the financial inflows or cost-sharing reimbursements received from a strategic partnership with Roche. This metric indicates the impact of collaborative agreements on the segment's net operating costs.